ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 80

The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

Kyoko Kawahara1, Tomoyuki Mukai 2, Akiko Nagasu 1, Masanori Iseki 3, Hajime Nagasu 4, Shoko Tshuji 1, Takahiko Akagi 1, Yasuyoshi Ueki 5 and Yoshitaka Morita 1, 1Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Japan, 2Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan, 3Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Nephrology and Hypertension, Kawasaki medical School, Kurashiki, Okayama, Japan, 5Department of Biomedical Sciences and Comprehensive Care Indiana University School of Dentistry, Indianapolis, IN

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantibodies, B6.Faslpr and double negative T cells, SH3BP2, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Animal Models Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: An adaptor protein SH3BP2 (Src homology 3 domain-binding protein 2) is widely expressed in immune cells and controls intracellular signaling pathways, such as Syk, Src, Vav, and PLCγ. In previous reports, SH3BP2 has been reported to regulate the production of antibodies in B cells. We have previously reported that, in a collagen-induced arthritis model, SH3BP2 loss-of-function mutation suppresses antibody production against type II collagen and markedly prevents the development of arthritis (Mukai T, et al. Arthritis Rheumatol 2015). To further investigate the role of SH3BP2 in autoimmune diseases, we examine the effect of SH3BP2 deficiency in a murine systemic lupus erythematosus (SLE) model.

Methods: For the lupus model, we used Faslpr mice (C57BL6 background), which possess impaired Fas signaling. SH3BP2-deficient mice and Faslpr mice were crossed to create SH3BP2-deficient Faslpr double mutant mice. These mice were observed until 35-week old, and then serum, urine, spleen, inguinal lymph nodes, kidney and bone marrow samples were collected. We evaluated proteinuria, splenomegaly, serum anti-dsDNA antibody titer, and histological renal damage. In addition, we analyzed B- and T-cell subsets by flow cytometry.

Results: Wild-type, SH3BP2-deficient, Faslpr, and SH3BP2-deficient Faslpr double mutant mice were analyzed. Faslpr mice exhibited splenomegaly, proliferative glomerulus lesions, and increased anti-dsDNA antibody levels compared to wild-type and Faslpr mice. All of them were significantly ameliorated by SH3BP2 deficiency. Furthermore, SH3BP2 deficiency suppressed the accumulation of CD3+B220+CD4−CD8−(double negative) T cells in spleen and lymph nodes, which are characteristic of Faslpr mice.

Conclusion: In the murine lupus model, SH3BP2 deficiency suppressed the development of the autoantibody (anti-dsDNA antibody), organ damage, and the accumulation of double negative T cells in the spleen. SH3BP2 could be a potential therapeutic target for autoimmune diseases.


Disclosure: K. Kawahara, Chugai Pharmaceutical Co., Ltd., 2, Glaxo Smith Kline K.K., 2; T. Mukai, Chugai Pharmaceutical Co., Ltd., 2, Glaxo Smith Kline K.K., 2; A. Nagasu, Chugai Pharmaceutical Co., Ltd., 2, Glaxo Smith Kline K.K., 2; M. Iseki, None; H. Nagasu, None; S. Tshuji, Chugai Pharmaceutical Co., Ltd., 2, Glaxo Smith Kline K.K., 2; T. Akagi, Chugai Pharmaceutical Co., Ltd., Glaxo Smith Kline K.K., 2; Y. Ueki, None; Y. Morita, Chugai Pharmaceutical Co., Ltd., 2, Glaxo Smith Kline K.K., 2.

To cite this abstract in AMA style:

Kawahara K, Mukai T, Nagasu A, Iseki M, Nagasu H, Tshuji S, Akagi T, Ueki Y, Morita Y. The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-role-of-adopter-protein-sh3bp2-in-a-murine-systemic-lupus-erythematosus-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-adopter-protein-sh3bp2-in-a-murine-systemic-lupus-erythematosus-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology